Serum Collection Study for Assay Development

Phase 1RecruitingNCT07205289

GPN Vaccines12 enrolled

Overview

The study will collect serum from 12 participants vaccinated with Gamma-PN to assist with assay development and validation

The study will collect serum from 12 participants vaccinated with Gamma-PN to assist with assay development and validation Participants will receive a dose of Gamma-PN and serum will be collected pre dose and Day 28

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Pneumococcal Disease, Invasive Pneumococcal Disease

Interventions

Gamma-PNBIOLOGICAL

Killed whole-cell pneumococcal vaccine

Eligibility

Sex: ALLMin age: 18 YearsMax age: 69 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * good general health Exclusion Criteria: * no previous pneumococcal vaccine

Locations (1)

University of Adelaide Clinical Research Facility

Adelaide, South Australia, Australia

RECRUITING

Outcomes

Primary Outcomes

OPA

Opsonophagocytic assay

Time frame: 6 months

Central Contacts

Nerissa Lakhan, PhD

CONTACT

+61-432 161 783 nerissa@gpnvaccines.com

Paul E Rolan, MD

CONTACT

+61-405 670 420 paul@gpnvaccines.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.